This is an aggregated industry headline. Read the full story at FiercePharma →
Lilly touts 'encouraging' early days for Foundayo obesity launch, even as GLP-1 pill appears to lag Novo's
As Eli Lilly gets off to the races with the launch of its flagship oral GLP-1 Foundayo, the Indianapolis drugmaker—and at least one set of analysts—isn’t sweating what appears to be a slower-than-expected liftoff compared with Novo Nordisk’s rival Wegovy pill.
By FiercePharma
· May 1, 2026
· via FiercePharma
Image: FiercePharma
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
moneyformat:headlineheadlineFiercePharma
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Money
All Money →
MoneyBioPharma Dive ↗
Research Alliance III follows a few months after Cormorant Asset Management priced a $150 million IPO for its …
MoneyFierceBiotech ↗
If any proof was needed that big money is still available for AI drug development, look no further than the 10…
MoneyFiercePharma ↗
CSL has slashed its revenue projection for the fiscal year from $15.8 billion to $15.2 billion, in another ind…